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Implication for health policy/practice/research/medical education:
Nephropathy is a common complication of  diabetes, so management of  it could lead to decreasing of  mortality and morbidity 
of  the patients. In addition of  angiotensin converting enzyme inhibitors and angiotensin receptor blockers, other drugs such 
as spironolactone, statins, and allopurinol were used for management of  diabetic nephropathy with acceptable results in some 
studies. Vitamin D metabolites may have renoprotective and anti-proteinuric effect, decreasing of  insulin resistance and blood 
pressure lowering effect, as well. Pearl of  vitamin D is an inexpensive, safe and probably effective drug for patients with 
diabetic nephropathy and vitamin D deficiency.    
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Background: Vitamin D (Vit D) deficiency is a common disorder in diabetic patients and 
may be a risk factor for ischemic heart disease and exacerbation of diabetic nephropathy 
(DN).
Objectives: The aim of this study was to evaluate the effect of Vit D3 therapy on proteinuria 
in type 2 diabetic patients with deficient or insufficient serum Vit D. 
Patients and Methods: In a double blind clinical trial, 60 type 2 diabetic patients with proteinuria 
greater than 150 mg/day who had Vit D deficiency or insufficiency were randomly enrolled 
in two equal groups. Pearl of Vit D as 50 000 IU/week and placebo (1 tablet per week) were 
prescribed in patients of case and control groups respectively for 8 weeks. At the beginning 
and 2 months later, 24 hours urine protein was checked in all patients. 
Results: There is no difference between serums Vit D level in case and control group at the 
beginning of the study, however at the end of the study serum Vit D level was significantly 
higher in the case group. There is no difference in proteinuria between case and control 
group at the beginning and the end of the study, while a significant difference between 
the changes of proteinuria before and after the study was seen in two groups (P = 0.028).
Conclusions: Vit D deficiency may exacerbate proteinuric and DN, hence correction of Vit D 
deficiency may decrease proteinuria in diabetic patients with nephropathy.
ABSTRACT
1. Background
The prevalence of  diabetes Mellitus (DM) world-
wide was 2.8% and total number of  patients was 171 
million in 2000. There are continuing increase in the 
prevalence and incidence of  DM, while the incidence 
of  DM was 7.1% in 2012 (1). Diabetic nephropathy 
(DN) is the most common cause of  chronic kidney 
disease and end stage renal disease, as about 30% to 
35% of  dialysis patients have diabetes (2). Diabetes 
is also the most common cause of  renal replacement 
therapy requirement, in the United States (3). One of 
the common and serious complications of  diabetes is 
nephropathy, defined by the development of  protein-
uria and classified based on the severity of  proteinuria 
as microalbuminuria and macroalbuminuria. With on-
set of  proteinuria, glomerular filtration rate decreased 
gradually at the rate of  10-12 mL annually or 1ml 
monthly (4,5). Lifestyle modifications (such as regu-
lar exercise, weight loss in obese patients, limitation 
of  salt and alcohol intake, and restriction of  dietary 
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protein intake), blood pressure and serum glucose 
controlling may have a role in the prevention of  DN 
(6). The basic drug treatment of  DN is inhibition of 
the renin–angiotensin aldosterone system with ACE 
inhibitors or angiotensin II–receptor blockers. Com-
bination of  angiotensin converting inhibitors plus 
angiotensin receptor blockers (dual system blocking) 
was shown more effective than single agent therapy in 
some studies (7). There are a few novel modalities for 
treatment of  DN, for example, aliskiren, a direct renin 
inhibitor has shown the anti-proteinuric effect in dia-
betic patients (8). Non-dihydropyridine calcium chan-
nel blockers such as diltiazem also have renoprotective 
effect probably due to decreasing hyperfiltration and 
intra-glomerular pressure (9), in addition, fenofibrate 
was shown to be effective in reducing proteinuria in 
small clinical trials (10). Serum level of  uric acid may 
be greater in DN patients compared to normal pop-
ulation (11), thus allopurinol was shown to be effec-
tive in reducing proteinuria in type 2 diabetic patients 
(12). Spironolactone an aldosterone receptor blocker 
probably has renoprotective effect due to its anti-in-
flammatory property (13). In addition, combination 
of  spironolactone and hydrochlorothiazide may be 
effective in DN treatment (14).
Vitamin D (Vit D) deficiency is a common disorder in 
diabetic patients and may be a risk factor for ischemic 
heart disease, deterioration of  chronic kidney disease 
and DN (15). 
Vit D metabolites may have a role in the inhibition 
of  the renin-angiotensin system and renoprotective 
effect by preventing of  glomerulosclerosis and an-
ti-proteinuric effect. Furthermore, prescription of  Vit 
D has shown decrease in insulin resistance and de-
crease in blood pressure as well (16,17). 
2. Objectives
Recently, some studies were carried out regarding to 
effect of  Vit D supplementation on reducing protein-
uria in diabetic patients. However the results of  these 
studies are controversial. Therefore, we aimed to eval-
uate effect of  Vit D in reducing proteinuria in the type 
2 diabetic patients with 25 (OH) Vit D deficiency or 
insufficient.
3. Patients and Methods 
3.1. Study patients
In this double-blind randomized clinical trial, 60 type 
2 diabetic patients were randomly enrolled in two 
equal case and control groups. Inclusion criteria were: 
proteinuria greater than 150 mg/dl, glomerular filtra-
tion ratio greater than 50 mL/min or serum creatinine 
< 2 mg/dL and Vit D deficiency (Vit D <25 nmol/L) 
or insufficiency (Vit D between 25 and 75 nmol/L). 
Exclusion criteria including; noncooperation of  the 
patients during the study, Ca × Phosphorus >55mg2/
dL2, of  Vit D or Ca supplement consumption during 
2 recent months and Ca>10 mg/dL. In 30 patients in 
case group, Vit D 50 000 IU was weekly prescribed for 
8 weeks. For 30 patients in control groups, placebo 
was prescribed similar to control group (weekly for 
8 weeks). Demographic criteria of  the patients were 
obtained and fasting blood sugar (FBS), glycosylated 
hemoglobin (HbA1C), Ca, phosphorus (P), Albumin, 
and 25 (OH) Vit D were checked in the beginning and 
at the end of  the study in all of  the patients. Urine 
protein was measured also in the end of  the study for 
all of  the patients. 
3.2. Ethical issues
1) The research followed the tenets of  the Declaration 
of  Helsinki; 2) informed consent was obtained, and 
they were free to leave the study at any time and 3) 
the research was approved by the ethical committee of 
Shahrekord University of  Medical Sciences (Ethical 
cod:1128 and IRCT code: IRCT2015081723656N1).
3.3. Statistical analysis
At the end of  the study, data were entered to SPSS 
software, (version 21.0, SPSS Inc, Chicago, IL, USA). 
Then data were analyzed for comparisons of  groups 
using the chi-square test, and independent and paired 
t test, and P values less than 0.5 were considered sig-
nificant. All information was remaining confidential, 
so written consent forms were filled in by all cases. 
The study was done under permission and support of 
research deputy of  Shahrekord University of  Medical 
Sciences. 
4. Results
Fifty-seven patients were participated in this study and 
3 patients were left due to non-cooperation and with-
drawal of  one patient of  case group and 2 patients 
of  control group. Twelve patients of  case group and 
18 patients of  control group were female and other 
were male (P = 0.120). Mean age of  case and control 
groups were 62.9 ± 9.3 and 62.4 ± 9 years respective-
ly (P = 0.85). At the beginning of  study, mean se-
rum level of  Vit D in case and control groups were 
36.76 ± 19.16 (nmol/L) and 32.19 ± 17.76 (nmol/L), 
respectively (P = 0.33). However at the end of  the 
study mean serum level of  Vit D was 89.44 ± 34.35 
(nmol/L) and 38.02 ± 23.90 (nmol/L) in the case and 
control groups, respectively (P = 0.0001). There was a 
significant difference between serum level of  Vit D 
before and after the study in the case group (P = 0.001) 
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as well as control group (P = 0.02). As shown in Table 
1, mean level of  proteinuria in the patients of  case 
group and control group were 962.62 ± 885.99 mg/day 
and 755.71 ± 640.94 mg/day, respectively (P = 0.70). 
While, at the end of  the study, it was 892.24  ± 879.40 
(mg/day) and 971.60  ± 940.24, respectively (P = 0.48). 
Difference of  proteinuria before and after the study 
in the case and control groups were 70.38  ± 553.71 
and 215.89  ± 451.44, respectively (P = 0.028), which 
revealed a significant difference among them. There 
were no significant difference between two groups of 
the patients based on FBS, HbA1C, ESR and CRP lev-
els (P > 0.05). 
5. Discussion
The study showed significant difference between 
changes of  proteinuria between 2 groups of  the pa-
tients during the study (P = 0.028), thus we concluded 
that prescription of  Vit D in type 2 diabetic patients 
Table 1. Comparison of  variables in two groups of  patients before and after the study
Variable Case group Control group P
Vit D 
(nmol/L)
Before 36.76  ±  19.16 32.19 ± 17.76 0.326
After 89.44 ± 34.35 38.02 ± 23.90 0.0001
P 0.0001 0.02 -
Before and after difference 52.68 ± 27.48 5.82 ± 14.08 <0.001
Proteinuria
(mg/day)
Before 962.62 ± 885.99 775.71 ± 640.94 0.702
After 892.24 ± 879.40 971.60 ± 940.24 0.482
P 0.27 0.025 -
Before and after difference 70.38 ± 553.71 215.89 ± 451.44 0.028
HbA1c (%)
Before 7.82 ± 0.86 8.14 ± 1.26 0.318
After 8.02 ± 1.23 8.10 ± 0.96 0.523
P 0.259 0.895 -
Before and after difference 0.2 ± 0.99 0.04 ± 1.05 0.406
FBS (mg/dL)
Before 146.69 ± 53.03 151.50 ± 52.35 0.571
After 152.72 ± 49.4 154.89 ± 73.26 0.354
P 0.482 0.882 -
Before and after difference 6.03 ± 35.54 3.39 ± 60.05 0.544
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Figure 1. The mean of  proteinuria during the study in the 
case and control group.
with nephropathy and Vit D deficiency may decreased 
proteinuria (Figure 1).
Prevalence of  Vit D deficiency is higher in diabetic 
patients, in addition association of  Vit D deficiency or 
Vit D insufficiency with the DN was reported in some 
studies. (15,18). Vit D deficiency may be associated 
with other microvascular complication of  diabetes 
such as diabetic retinopathy (19).
In addition to angiotensin converting enzyme inhib-
itors and angiotensin receptor blockers, other drugs 
such as spironolactone (aldosterone receptor blocker)
(14), non- dihydropyridine calcium channel blockers 
(diltiazem), antihyperlipidemic agents (20), allopurinol 
(12) were used in the treatment of  DN.
Effect of  Vit D prescription in DN was evaluated in 
some clinical and experimental studies with contro-
versial results. Ahmadi et al, in a clinical trial on 51 
diabetic patients with DN and Vit D3 deficiency, it was 
found that Vit D3 prescription for three months had 
not any effect on decreasing of  proteinuria (21).
Kim et al in the study on 63 diabetic patients with 
nephropathy and low level of  serum Vit D during sev-
en months showed that repletion with cholecalciferol 
could decrease albuminuria. They concluded that di-
etary Vit D in patients with DN may have a beneficial 
effect in delaying the progression of  disease (22).
In a study by Bonakdaran et al, of  119 diabetic pa-
tients, 31 cases had Vit D deficiency, any significant 
reduction in the proteinuria after using of  calcitriol for 
8 weeks was detected (23).
In a study by De Zeeuw et al, on 281 diabetic patients, 
they could show that 2 mg/day of  paricalcitol in ad-
dition of  rennin-angiotensin-aldosterone blockers, 
could decrease proteinuria (24).
In another rstudy by Huang et al deficiency of  serum 
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25(OH) Vit D3 levels was associated with microal-
buminuria, and administration of  cholecalciferol sig-
nificantly decreased albuminuria in the early stages of 
treatment. They concluded that conventional doses 
of  cholecalciferol may have antiproteinuric effects on 
Chinese diabetic patients (25).
We found no association between using of  Vit D and 
serum Hb A1c, however different results were reported 
in other studies, for example, in Madar et al. 16-week 
administration of  Vit D3 to healthy individuals with 
low Vit D status showed no improvement for HbA1c 
(26). Likewise, Ahmadi et al reported no significant 
difference based on HbA1C in both case and control 
groups (21). Otherwise Bonakdaran et al showed a sig-
nificant reduction in HbA1c in diabetic patients (23).
6. Conclusions
Administration of  Vit D in type 2 diabetic patients 
with Vit D deficiency or insufficiency leads to normal-
ization of  serum Vit D level and decrease proteinuria 
compared to control group, however we did not show 
any improvement of  glycemic control indices in the 
patients. Thus, we concluded that, correction of  Vit 
D deficiency may be an effective and safe modality of 
treatment for DN.
Limitations of  the study
Small proportion of  the patients was a limitation of 
our study. 
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